Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
This rapid weight loss from GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) decreases the amount of subcutaneous fat faster than skin can adjust
Though with similar effects as some pre-existing drugs (semaglutide, liraglutide, exenatide, etc.) targeting diabetes and obesity, tirzepatide is considered a first-in-class medication for demonstrating action on both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors
All proposed mechanisms remain theoretical and under investigation
Weeks 14 0.25 mg Starter dose weekly Weeks 58 0.5 mg Increased weekly Weeks 916 1.0 mg Therapeutic dose Weeks 17+ 2.0 mg Maintenance dose Injection method Subcutaneous (under the skin) Frequency Once per week Provider check-ins Monthly dose adjustments Timeline 20 weeks to full dose What to expect Weight loss milestones and what patients typically experience at each phase
Cheminform 15 (1), 69
Health outcomes favored semaglutide, which provided an additional 0.09 QALYs (13.90 vs
US$ 26.61
US$ 23.33
US$ 20.40
US$ 21.65
US$ 25.17
US$ 24.17
US$ 20.42
